Premier Biomedical (OTCQB:BIEI) shared the publication of an update letter to shareholders from the company’s CEO William Hartman.
As quoted in the press release:
- This first half, we cleared our books of convertible debt, launched a revenue-generating product line, and secured more conventional financing with incentives for the lender to appreciate, rather than depreciate our stock price.
- We established a number of direct distributors, including pharmacies and health clinics.
- Now that we have resolved the product formulations and volume manufacturing to our specifications, we are attempting to expand our distributor networks both within North America as well as off-shore.
- We are in the process of developing, and launching several additional pain relieving products which we intend to spot-market test.
We have been very busy building our business, and now that we have resolved the basic issue of developing an industry-best formulation and a volume manufacturing system, we are poised to expand our business geometrically. We thank our loyal stockholders and pledge that we will continue our efforts on their behalf. We thank you for your continued support.